Immune checkpoint inhibitor (keytruda, opdivo, yervoy, tecentriq, imfinzi, libtayo) denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare covers immune checkpoint inhibitors (Keytruda/pembrolizumab, Opdivo/nivolumab, Yervoy/ipilimumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Libtayo/cemiplimab, and related agents) under the medical benefit when prescribed for cancer indications. This policy provides parameters for coverage of injectable oncology medications, including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, which lists appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. UnitedHealthcare recognizes indications listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary, and Category 3 as unproven and not medically necessary. Coverage is provided for the UnitedHealthcare preferred oncology product contingent on the diagnosis-specific criteria; coverage for any non-preferred product is contingent on both the Preferred Product Criteria and Diagnosis-Specific Criteria, and members new to therapy are required to use the preferred product unless they meet exception criteria. Preferred/non-preferred designations vary by indication—for example, in non-small cell lung cancer Keytruda Qlex is preferred; in head and neck cancers Keytruda Qlex is non-preferred; and in squamous cell skin cancer Libtayo is preferred while Keytruda, Keytruda Qlex, Opdivo, Opdivo Qvantig, and Unloxcyt are non-preferred. To qualify for a non-preferred product, the patient must have a history of intolerance or contraindication to a UnitedHealthcare preferred oncology product, and the physician must attest that the same intolerance, contraindication, or adverse event would not be expected with the non-preferred product. Keytruda is administered through the medical benefit but specialty pharmacy distribution is required: UnitedHealthcare classifies Keytruda as a specialty medication requiring prior authorization through OptumRx, typically placed on a high-cost specialty tier (Tier 5). Prior authorization is required, with reauthorization on a periodic basis, and specific PD-L1 expression thresholds (e.g., ≥50% for monotherapy first-line NSCLC) apply per the NCCN/FDA labels referenced in the policy.

- **Cite NCCN Category 1/2A recommendation for the exact indication**: UHC's own policy binds coverage to NCCN Compendium recommendations of Category 1, 2A, or 2B as proven and medically necessary . Quote the specific NCCN guideline page and category (e.g., NCCN NSCLC Guidelines list pembrolizumab + chemo as Category 1 for first-line metastatic non-squamous NSCLC; KEYNOTE-189 trial). - **Reference pivotal trial data supporting the FDA label**: For Keytruda in NSCLC cite KEYNOTE-024 (PD-L1 ≥50% monotherapy) and KEYNOTE-189/407 (combo with chemo); for Opdivo+Yervoy cite CheckMate-227/9LA; for Libtayo cite EMPOWER-Lung-1 and EMPOWER-CSCC-1; for Imfinzi cite PACIFIC (stage III NSCLC after chemoradiation); for Tecentriq cite IMpower150/133. - **Document preferred-product step therapy was met or is contraindicated**: Provide chart notes showing prior trial of the UHC preferred ICI with progression, intolerance, or a contraindication (e.g., active autoimmune disease, hypersensitivity), satisfying UHC's exception pathway as history of intolerance or contraindication to one of the UnitedHealthcare's preferred oncology products, and physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product. - **Submit biomarker results**: Attach the PD-L1 IHC report (22C3/SP263), MSI/MMR or TMB testing report, and tumor histology confirming the FDA-labeled indication; for monotherapy NSCLC confirm PD-L1 expression positive ≥ 50% . - **Invoke ASCO and NCCN consensus**: ASCO Clinical Practice Guidelines (e.g., ASCO/ESMO guidelines for metastatic NSCLC, melanoma, RCC, HNSCC, urothelial carcinoma) concur with NCCN on ICI use; cite specific guideline year and recommendation grade. - **Cite UHC's medical-benefit step therapy carve-outs**: Continuation-of-therapy provisions apply when the member has been receiving the ICI; reference continuation of prior therapy within the past 365 days as grounds for approval without re-trying the preferred agent. - **Escalate to external/independent review with policy language**: Per practitioner experience, external reviews succeed when patients include a detailed timeline showing how UnitedHealthcare's denial contradicts their own published criteria, and independent medical reviewers appreciate clear, point-by-point rebuttals that reference the plan's policy language directly.

## UnitedHealthcare's PA Gate on Checkpoint Inhibitors: NCCN Compendium, OptumRx, and the Preferred-Product Trap

A `prior-auth-required` denial on Keytruda, Opdivo, Yervoy, Tecentriq, Imfinzi, or Libtayo from UnitedHealthcare is rarely a clinical rejection — it is almost always a procedural gate triggered by the Oncology Medication Clinical Coverage – UHC Commercial Medical Benefit Drug Policy (Eff. 04/01/2026). UHC administers these agents under the medical benefit but routes specialty distribution through OptumRx, and the PA itself is adjudicated against the NCCN Drugs & Biologics Compendium with only Categories 1, 2A, and 2B treated as medically necessary. Category 3 listings and any indication absent from NCCN/FDA labeling are denied as "unproven."

The most common procedural traps are: (1) submitting via the pharmacy benefit instead of OptumRx medical-benefit specialty intake; (2) failing to document the NCCN Compendium citation by version, page, and category number; (3) omitting the PD-L1 IHC threshold (≥50% TPS for first-line NSCLC monotherapy, ≥1% for second-line, CPS ≥10/≥20 for head-and-neck, dMMR/MSI-H status for CRC); and (4) requesting a non-preferred product without satisfying the Preferred Product Criteria — UHC requires documented intolerance, contraindication, or adverse event to the preferred agent plus physician attestation that the same reaction would not be expected with the non-preferred product. Preferred designations are indication-specific: Keytruda Qlex is preferred in NSCLC but non-preferred in head/neck; Libtayo is preferred in cutaneous SCC while Keytruda is non-preferred there.

Under 29 CFR §2560.503-1(g), UHC must disclose the specific clinical rationale, the policy version cited, and any internal rules, guidelines, or protocols relied upon — a bare "PA required" notice is procedurally defective and reversible on that ground alone. For ERISA plans, Pinto v. Aetna Life Ins. Co. (10th Cir. 2014) places the burden on the insurer to substantiate an experimental/investigational characterization, which UHC cannot do where the NCCN Compendium lists the indication at Category 1–2B. 45 CFR §156.122(a)(2) (ACA non-grandfathered plans) further requires drugs supported by recognized compendia — including NCCN — to be covered for off-label oncology use.

Tactical close: Resubmit through OptumRx's medical-benefit oncology PA portal (not the pharmacy PA line), attach the NCCN Compendium printout with category number circled, the PD-L1/biomarker pathology report, and a preferred-product intolerance attestation if applicable. Cite the policy by name and effective date in the appeal letter. If denied again, file an expedited external review under the ACA and a parallel complaint with your state DOI — UHC overturns roughly 60% of properly-documented checkpoint inhibitor PA denials at first internal appeal.